Adverse events196

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 196

Type	Event	Organ system	Group	Affected	At risk	Events
other	ANAEMIA	Blood and lymphatic system disorders	Placebo + Dacarbazine 1000 mg/m2	4	32	6
other	ANAEMIA	Blood and lymphatic system disorders	Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2	18	97	22
other	NEUTROPENIA	Blood and lymphatic system disorders	Placebo + Dacarbazine 1000 mg/m2	11	32	14
other	NEUTROPENIA	Blood and lymphatic system disorders	Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2	25	97	35
other	THROMBOCYTOPENIA	Blood and lymphatic system disorders	Placebo + Dacarbazine 1000 mg/m2	4	32	4
other	THROMBOCYTOPENIA	Blood and lymphatic system disorders	Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2	26	97	39
other	CONSTIPATION	Gastrointestinal disorders	Placebo + Dacarbazine 1000 mg/m2	14	32	19
other	CONSTIPATION	Gastrointestinal disorders	Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2	37	97	46
other	ASTHENIA	General disorders	Placebo + Dacarbazine 1000 mg/m2	4	32	5
other	ASTHENIA	General disorders	Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2	20	97	21
other	GAMMA-GLUTAMYLTRANSFERASE INCREASED	Investigations	Placebo + Dacarbazine 1000 mg/m2	2	32	3
other	GAMMA-GLUTAMYLTRANSFERASE INCREASED	Investigations	Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2	6	97	6
other	HYPERGLYCAEMIA	Metabolism and nutrition disorders	Placebo + Dacarbazine 1000 mg/m2	2	32	4
other	HYPERGLYCAEMIA	Metabolism and nutrition disorders	Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2	4	97	5
other	NECK PAIN	Musculoskeletal and connective tissue disorders	Placebo + Dacarbazine 1000 mg/m2	0	32	0
other	NECK PAIN	Musculoskeletal and connective tissue disorders	Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2	5	97	5
other	PAIN IN EXTREMITY	Musculoskeletal and connective tissue disorders	Placebo + Dacarbazine 1000 mg/m2	1	32	1
other	PAIN IN EXTREMITY	Musculoskeletal and connective tissue disorders	Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2	5	97	5
other	PARAESTHESIA	Nervous system disorders	Placebo + Dacarbazine 1000 mg/m2	2	32	4
other	PARAESTHESIA	Nervous system disorders	Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2	5	97	5

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01974752/events

API reference For AI assistants

Adverse events196

Sources 3

Read this list from software.